FindTrial
Sign In

Studying the pattern of androgen receptor and its link to tumor growth and cancer stage in people with colorectal cancer.

Assessing the utility of Androgen Receptor (AR) expression as a histopathological marker for tumor behavior in comparison to histopathological parameters and Tumor, Nodes and Metastasis staging in colorectal carcinoma. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/095655
Enrollment
50
Registered
2025-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified Health Condition 2: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Prakritee Sandilya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Already diagnosed as Colorectal carcinoma on histopathology. 2) All operated cases of colectomy/ hemicolectomy/ abdominoperineal resection with suitable lymph node dissection. 3) Primary cases of Colorectal carcinoma without any history of previous treatment. 4) All patients with Colorectal carcinoma arising de novo.

Exclusion criteria

Exclusion criteria: 1) All benign lesions of colon and rectum and other malignant carcinomas like neuroendocrine tumors and gastrointestinal stromal tumor. 2) All the already treated cases of Colorectal Carcinoma. 3) All patients with Colorectal carcinoma where the cancer is arising as a result of recurrence. 4) Patients with no histological confirmation of Colorectal Carcinoma. 5) All patients who have defaulted treatment

Design outcomes

Primary

MeasureTime frame
The study is expected to determine the significance of androgen receptor expression in colorectal carcinoma by correlating it with tumor behavior, histopathological grade, and TNM staging.Timepoint: 2 years—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Prakritee Sandilya

Jawaharlal Nehru Medical College, Wardha

samarth21174@gmail.com8830267710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026